Advertisement
U.S. markets open in 13 minutes
  • S&P Futures

    5,309.00
    +0.75 (+0.01%)
     
  • Dow Futures

    40,185.00
    +41.00 (+0.10%)
     
  • Nasdaq Futures

    18,502.50
    -1.25 (-0.01%)
     
  • Russell 2000 Futures

    2,141.70
    +3.30 (+0.15%)
     
  • Crude Oil

    82.65
    +1.30 (+1.60%)
     
  • Gold

    2,234.50
    +21.80 (+0.99%)
     
  • Silver

    24.83
    +0.08 (+0.34%)
     
  • EUR/USD

    1.0812
    -0.0018 (-0.16%)
     
  • 10-Yr Bond

    4.2100
    +0.0140 (+0.33%)
     
  • Vix

    12.95
    +0.17 (+1.33%)
     
  • GBP/USD

    1.2638
    -0.0000 (-0.00%)
     
  • USD/JPY

    151.3050
    +0.0590 (+0.04%)
     
  • Bitcoin USD

    70,705.47
    -502.84 (-0.71%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,954.70
    +22.72 (+0.29%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

FDA approves AstraZeneca's lung cancer drug as first-line treatment

July 13 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca Plc's drug, Iressa, as a first-line treatment for a common form of lung cancer.

The drug was previously approved for use in non-small cell lung cancer patients only after they did not respond to chemotherapy.

The FDA said on Tuesday the approval was based on results from a trial of 106 patients with previously untreated non-small cell lung cancer. (http://1.usa.gov/1Sjw5eo) (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)

Advertisement